Bancreek Capital Management LP Boosts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bancreek Capital Management LP lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,733 shares of the medical research company's stock after purchasing an additional 1,359 shares during the quarter. Thermo Fisher Scientific accounts for about 6.1% of Bancreek Capital Management LP's portfolio, making the stock its 4th largest position. Bancreek Capital Management LP's holdings in Thermo Fisher Scientific were worth $9,732,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. BDF Gestion acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $6,368,000. Nisa Investment Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 6.2% in the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company's stock worth $87,093,000 after purchasing an additional 8,180 shares during the last quarter. Lord Abbett & CO. LLC raised its position in Thermo Fisher Scientific by 1.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company's stock worth $45,478,000 after purchasing an additional 1,480 shares during the last quarter. Seven Eight Capital LP acquired a new position in Thermo Fisher Scientific during the 1st quarter worth about $1,161,000. Finally, ORG Partners LLC increased its stake in shares of Thermo Fisher Scientific by 216.6% in the second quarter. ORG Partners LLC now owns 1,640 shares of the medical research company's stock valued at $890,000 after buying an additional 1,122 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $2.01 during mid-day trading on Wednesday, hitting $542.76. 580,407 shares of the stock were exchanged, compared to its average volume of 1,458,753. Thermo Fisher Scientific Inc. has a 12 month low of $455.22 and a 12 month high of $627.88. The company has a 50-day simple moving average of $591.27 and a 200 day simple moving average of $583.32. The company has a market capitalization of $207.61 billion, a P/E ratio of 33.90, a P/E/G ratio of 3.57 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business's revenue was up .2% compared to the same quarter last year. During the same period last year, the firm posted $5.69 earnings per share. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific's dividend payout ratio is currently 9.78%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TMO shares. Raymond James increased their target price on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an "outperform" rating in a research report on Thursday, July 25th. Royal Bank of Canada lowered their target price on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Stephens assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an "overweight" rating and a $680.00 price objective for the company. UBS Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a research report on Monday, September 16th. Finally, Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a "buy" rating and a $680.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $649.33.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the business's stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,150 shares of company stock worth $20,651,865. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.